115 related articles for article (PubMed ID: 20206571)
1. [Economic assessment of pulsed dose-rate (PDR) brachytherapy with optimized dose distribution for cervix carcinoma].
Remonnay R; Morelle M; Pommier P; Haie-Meder C; Quetin P; Kerr C; Delannes M; Castelain B; Peignaux K; Kirova Y; Romestaing P; Williaume D; Krzisch C; Thomas L; Lang P; Baron MH; Cussac A; Lesaunier F; Maillard S; Barillot I; Charra-Brunaud C; Carrère MO; Peiffert D
Cancer Radiother; 2010 Jun; 14(3):161-8. PubMed ID: 20206571
[TBL] [Abstract][Full Text] [Related]
2. [Quality control in pulsed dose rate brachytherapy].
Métayer Y; Meyer P; Brunaud C; Peiffert D
Cancer Radiother; 2009 Jul; 13(4):318-22. PubMed ID: 19427253
[TBL] [Abstract][Full Text] [Related]
3. Time-resolved in vivo luminescence dosimetry for online error detection in pulsed dose-rate brachytherapy.
Andersen CE; Nielsen SK; Lindegaard JC; Tanderup K
Med Phys; 2009 Nov; 36(11):5033-43. PubMed ID: 19994514
[TBL] [Abstract][Full Text] [Related]
4. Optimized afterloading therapy of cervix carcinoma with the discontinuous movement of the iridium source.
Busch M; Dühmke E
Strahlenther Onkol; 1990 Sep; 166(9):591-4. PubMed ID: 2218862
[TBL] [Abstract][Full Text] [Related]
5. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
Pötter R; Knocke TH; Fellner C; Baldass M; Reinthaller A; Kucera H
Cancer Radiother; 2000; 4(2):159-72. PubMed ID: 10812362
[TBL] [Abstract][Full Text] [Related]
6. Retrospective dosimetric comparison of low-dose-rate and pulsed-dose-rate intracavitary brachytherapy using a tandem and mini-ovoids.
Mourtada F; Gifford KA; Berner PA; Horton JL; Price MJ; Lawyer AA; Eifel PJ
Med Dosim; 2007; 32(3):181-7. PubMed ID: 17707197
[TBL] [Abstract][Full Text] [Related]
7. A Medicare cost analysis of MRI- versus CT-based high-dose-rate brachytherapy of the cervix: Can MRI-based planning be less costly?
Bajaj A; Harmon G; Weaver J; Martin B; Mysz M; Surucu M; Roeske JC; Konski AA; Small W; Harkenrider MM
Brachytherapy; 2018; 17(2):326-333. PubMed ID: 29331574
[TBL] [Abstract][Full Text] [Related]
8. Intercomparison of treatment concepts for MR image assisted brachytherapy of cervical carcinoma based on GYN GEC-ESTRO recommendations.
Lang S; Nulens A; Briot E; Kirisits C; De Brabandere M; Dumas I; Dimopoulos J; Petrow P; Georg D; Van Limbergen E; Haie-Meder C; Pötter R
Radiother Oncol; 2006 Feb; 78(2):185-93. PubMed ID: 16466820
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma.
Lertsanguansinchai P; Lertbutsayanukul C; Shotelersuk K; Khorprasert C; Rojpornpradit P; Chottetanaprasith T; Srisuthep A; Suriyapee S; Jumpangern C; Tresukosol D; Charoonsantikul C
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1424-31. PubMed ID: 15275728
[TBL] [Abstract][Full Text] [Related]
10. [End of the commercialisation of (192)Ir wires in France: proposals of the groupe de Curiethérapie de la SFRO].
Peiffert D; Hannoun-Lévi JM; Oldrini S; Brunaud C
Cancer Radiother; 2014 Oct; 18(5-6):441-6. PubMed ID: 25218567
[TBL] [Abstract][Full Text] [Related]
11. High dose rate versus low dose rate brachytherapy for squamous cell carcinoma of the cervix: an economic analysis.
Jones G; Lukka H; O'Brien B
Br J Radiol; 1994 Nov; 67(803):1113-20. PubMed ID: 7820405
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for implementation of high dose rate 192Ir brachytherapy in developing countries by the Advisory Group of International Atomic Energy Agency.
Nag S; Dally M; de la Torre M; Tatsuzaki H; Kizilbash N; Kurusun S; Pinillos L; Pokrajac B; Sur R; Levin V
Radiother Oncol; 2002 Sep; 64(3):297-308. PubMed ID: 12242118
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of HDR (192Ir) versus MDR (137Cs) intracavitary brachytherapy for carcinoma of the uterine cervix.
Tanaka E; Oh RJ; Yamada Y; Shiomi H; Nakamura S; Shimamoto S; Teshima T; Inoue T; Inoue T
Brachytherapy; 2003; 2(2):85-90. PubMed ID: 15062145
[TBL] [Abstract][Full Text] [Related]
14. A multicentre audit of HDR/PDR brachytherapy absolute dosimetry in association with the INTERLACE trial (NCT015662405).
Díez P; Aird EGA; Sander T; Gouldstone CA; Sharpe PHG; Lee CD; Lowe G; Thomas RAS; Simnor T; Bownes P; Bidmead M; Gandon L; Eaton D; Palmer AL
Phys Med Biol; 2017 Nov; 62(23):8832-8849. PubMed ID: 28984277
[TBL] [Abstract][Full Text] [Related]
15. [Pulsed-dose rate brachytherapy in cervical cancers: why, how?].
Mazeron R; Dumas I; Martin V; Martinetti F; Benhabib-Boukhelif W; Gensse MC; Chargari C; Guemnie-Tafo A; Haie-Méder C
Cancer Radiother; 2014 Oct; 18(5-6):447-51. PubMed ID: 25155782
[TBL] [Abstract][Full Text] [Related]
16. Determination of air-kerma strength for the 192Ir GammaMedplus iX pulsed-dose-rate brachytherapy source.
Riley AD; Pike TL; Micka JA; Fulkerson RK; DeWerd LA
Med Phys; 2013 Jul; 40(7):071732. PubMed ID: 23822436
[TBL] [Abstract][Full Text] [Related]
17. Low morbidity following 9,000-rad intracavitary endocurietherapy (ECT) using the Kumar Cervical Applicator and external-beam radiotherapy (EXRT) in the management of carcinoma of the uterine cervix.
Kumar PP; Good RR; Scott JC; Jones EO; Lynch G; McCaul GF
Radiat Med; 1988; 6(2):92-106. PubMed ID: 3140299
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the expected costs of high dose rate brachytherapy using 252Cf versus 192Ir.
Rivard MJ; Kirk BL; Stapleford LJ; Wazer DE
Appl Radiat Isot; 2004 Dec; 61(6):1211-6. PubMed ID: 15388112
[TBL] [Abstract][Full Text] [Related]
19. MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer.
Lindegaard JC; Tanderup K; Nielsen SK; Haack S; Gelineck J
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):756-64. PubMed ID: 18191335
[TBL] [Abstract][Full Text] [Related]
20. Pulsed-dose-rate intracavitary brachytherapy for cervical carcinoma: the AIIMS experience.
Rath GK; Sharma DN; Julka PK; Subramani V; Bahl A; Haresh KP
Am J Clin Oncol; 2010 Jun; 33(3):238-41. PubMed ID: 19841576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
